Endocrine Abstracts

Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...

Nelson’s syndrome (NS) is a potentially severe complication following bilateral adrenalectomy for Cushing’s disease (CD). Series assessing outcomes of treatments for NS are limited by small sample size, often short follow-up and variability of success criteria. We performed a UK multi-centre study aiming to review outcomes of primary treatment for NS. Clinical, laboratory, imaging data were collected. Kaplan-Meier method, log-rank test, Cox regression analysis were u...

Corticotropin-releasing hormone (CRH), a 41-aminoacid peptide that is mainly produced in the hypothalamic paraventricular nucleus (PVN), plays a crucial role in stress response and is considered to be the central driving force in the activity of hypothalamic–pituitary–adrenal (HPA) axis. Previous studies of neuronal input to the PVN were limited by experimental techniques and could not be restricted by a single neuron type. In the present study, by using a novel defi...

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...